Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
Deutsche Version Deutsche Version
  MedUni Vienna    Intranet    MedUni Vienna - Shop    University Library    University Hospital Vienna  
 
Krebsforschung_EN.png
 
 
 
Hauptnavigation
  • Home
  • Mission Statement
    • Chronik
    • 50 Jahre Institut für Krebsforschung
    • Imagevideo: Institut für Krebsforschung
  • Forschung
    • Forschungsschwerpunkte
    • Forschungsgruppen
    • Wissenschaftliche Services - Core Facilities
  • Lehre
    • Vorlesungen und Seminare des Institutes
    • Universitätslehrgang Toxikologie für Postgraduierte
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Programm Malignant Diseases
    • PhD Programm Clinical and Experimental Oncology
  • Kontakt
    • Kontakt
    • Lageplan
 
Forschung / Forschungsschwerpunkte / Angewandte und experimentelle Onkologie / Walter Berger / Research Projects / FGFs and FGFRs as Targets for Anticancer Therapy in Lung Cancer and Glioblastoma
 
Subnavigation
  • Forschungsschwerpunkte
    • Zelluläre und molekulare Tumorbiologie
    • Angewandte und experimentelle Onkologie
      • Walter Berger
        • Research Projects
        • Group Members
      • Martin Filipits
      • Petra Heffeter
      • Michael Grusch
      • Klaus Holzmann
      • Hedwig Sutterlüty
    • Sicherheit chemischer Substanzen und Krebsprävention
    • Progression und Metastasierung von Tumoren
  • Forschungsgruppen
  • Wissenschaftliche Services - Core Facilities


Inhaltsbereich

FGFs and FGFRs as Targets for Anticancer Therapy in Lung Cancer and Glioblastoma

Aim of this research project is to clarify the role of fibroblast growth factor (FGF) receptor-dependent signals in development and malignant progression of major solid tumor types with a focus lung cancer and glioblastomas and their potential as targets for anticancer strategies. In lung cancer, resistance development against FGFR inhibitors in squamous cell carcinoma with FGFR1 amplification is followed. Moreover, a major focus is laid on the impact of FGFR4 on the aggressiveness of solid tumors with a focus on lung cancer.

Inhibition of specific FGFRs by dominant negative (dn) or kinase dead (kd) adenoviral constructs prolongs survival of SCID mice bearing a human glioblastoma xenograft.


Claudia Engelmaier,
PhD
N.N., Master Student

Cooperations:
B. Grasl-Kraupp, M. Grusch, K. Holzmann, B. Marian
(Institute of Cancer Research)
G. Widhalm, S. Wolfsberger, E. Knosp (AKH, Department for Neurosurgery)
J. Hainfellner (AKH, Department for Neuropathology)
S. Spiegl-Kreinecker, G.Wurm (Landesnervenklinik Wagner-Jauregg, Linz)
AKH Vienna

 
Print
 
 
© MedUni Wien | Publishing information | Terms of use | Data Protection | Accessibility | Contact